Johnson & Johnson announces study of OTTAVA System met primary endpoints

Johnson & Johnson announced results from the first clinical study of the investigational OTTAVA Robotic Surgical System. The results were presented at the 2026 American Society for Metabolic and Bariatric Surgery Annual Meeting. In the 30-patient cohort, the study met its primary safety and performance endpoints through 30 days post-procedure, and investigators completed all procedures robotically on OTTAVA without conversion to a non-robotic approach. Average weight loss by 30 days after surgery was 30 pounds. These clinical data, together with preclinical testing, were used to support an application to the U.S. Food and Drug Administration for De Novo classification targeting an indication covering multiple procedures in general surgery within the upper abdomen, such as gastric bypass, gastric sleeve, small bowel resection and hiatal hernia repair.